ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Feb 03, 2023 11:01 JST
Source:
Ocumension Therapeutics
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202
HONG KONG, Feb 03, 2023 - (ACN Newswire) - Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully.
The phase I clinical trial of OT-202 was designed as a randomized, double-masked, placebo-controlled clinical trial on the safety, tolerance and pharmacokinetic properties of its single/multiple administration on healthy adult subjects in China.
Mr. Ye LIU, the Executive Director and CEO of Ocumension Therapeutics said, "OT-202 (tyrosine kinase inhibitor) is a class I innovative drug developed by the Company for the treatment of moderate to severe dry eye. A total of 30 subjects were enrolled for the phase I clinical trial in China. OT-202 demonstrated good safety and tolerability profile in healthy adult subjects in the phase I clinical trial. Currently, we are in the process of advancing the study for the phase II clinical trial."
The mechanism of action of OT-202 is that the dual-targeted inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor achieves a synergistic effect in the treatment of dry eye diseases and inhibits the inflammatory response.
More information about Ocumension Therapeutics:
https://www.ocumension.com/
Source: Ocumension Therapeutics
Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
TANAKA Holds Press Conference to Commemorate Its 140th Anniversary
Aug 15, 2025 03:00 JST
Mitsubishi Corporation to acquire shares in Copper World copper mine project in the US
Aug 14, 2025 12:05 JST
Team Mitsubishi Ralliart Conducts Shakedown Ahead of Asia Cross Country Rally 2025: Targeting First Overall Championship in Three Years
Aug 07, 2025 18:40 JST
Toyota to Establish New Vehicle Manufacturing Plant in Japan
Aug 07, 2025 18:31 JST
MHI Heat Pumps NZ Wins People's Choice Award for Third Year Running
Aug 07, 2025 17:32 JST
FWD Group completes build-out of high-net-worth hub in Asia
Aug 07, 2025 14:00 JST
Shoucheng Highlights VC Role and Robot Lineup at WRC 2025
Aug 07, 2025 10:50 JST
Fastport eQuad, Flagship Product from New Honda Business Venture, Wins "Red Dot: Best of the Best 2025" Award in Red Dot Award: Design Concept
Aug 06, 2025 19:40 JST
Dream Incubator and DENSO Launch Demonstration Project for Digital Platform Development for Mobility Circular Economy and Integrated Manufacturing for India
Aug 06, 2025 18:54 JST
Fujitsu's CHRO Roundtable Report 2025 highlights data-driven HRBP practices for human capital management
Aug 06, 2025 11:00 JST
MHI Selected to Enter Next Stage Procurement Process for Australia's New General-Purpose Frigates
Aug 05, 2025 22:02 JST
12 New Companies Join Toyota Woven City as Inventors
Aug 04, 2025 21:09 JST
Honda HRC Wins 46th Suzuka 8 Hours Endurance Road Race
Aug 04, 2025 20:43 JST
MUFG Bank and Fujitsu collaborate on preventive health ecosystem to address societal challenges
Aug 04, 2025 11:00 JST
Hitachi completes capital reorganization of air conditioning joint venture accelerating the deployment of green cooling solutions through "One Hitachi"
Aug 01, 2025 19:00 JST
Mitsubishi Motors and Security Bank launch Mitsubishi Motors Finance Philippines Inc.
Aug 01, 2025 17:00 JST
Honda Turkiye A.S. decided to establish Motorcycle Production Factory
Aug 01, 2025 16:45 JST
Honda Begins Joint Demonstration of Stationary Fuel Cell Power Station Designed to Utilize By-product Hydrogen and Repurposed Automotive Fuel Cells
Aug 01, 2025 11:20 JST
Isuzu's first battery-electric pickup "D-MAX EV" adopts eAxle
Aug 01, 2025 11:00 JST
Fujitsu starts official development of plus-10,000 qubit superconducting quantum computer targeting completion in 2030
Aug 01, 2025 10:20 JST
More Latest Release >>
Related Release
Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema
December 20 2023 20:51 JST
Ocumension Therapeutics Announces 2023 Interim Results
August 24 2023 23:35 JST
Ocumension Therapeutics Announces 2022 Annual Results
March 30 2023 22:29 JST
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
March 13 2023 18:30 JST
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results
February 14 2023 10:57 JST
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China
February 01 2023 10:00 JST
Ocumension Therapeutics Appoints Mr. Tim RUAN and Mr. WANG Chong as Chief Financial Officer and Head of Investor Relations respectively
January 30 2023 11:38 JST
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results
March 20 2021 10:10 JST
More Press release >>